SNT 6.67% 2.8¢ syntara limited

time frame, page-4

  1. 509 Posts.
    My mistake.
    U.S. FDA ACCEPTS ARIDOLTM NEW DRUG APPLICATION FOR REVIEW
    Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced it had received notification from the United
    States Food and Drug Administration (FDA) that the New Drug Application (NDA) for its mannitol
    bronchial challenge test Aridol™ has been accepted for standard review. The FDA will advise the
    result of the review on 27 December 2009.

 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.